Seung-Beom Hong

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Epithelial Mesenchymal Transition

Inflammatory Response

Epidermal Growth Factor Receptor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Seung-Hwan Lee, Young-Ho Choi, Soon Myung Kang, Min-Gyu Lee, Arnaud Debin, Eric Perouzel, Seung-Beom Hong, Dong-Ho Kim
The Defined TLR3 Agonist, Nexavant, Exhibits Anti-Cancer Efficacy and Potentiates Anti-PD-1 Antibody Therapy by Enhancing Immune Cell Infiltration. Cancers 15 (24) (2023)
Seung-Hwan Lee, Young-Ho Choi, Soon Myung Kang, Min-Gyu Lee, Arnaud Debin, Eric Perouzel, Seung-Beom Hong, Dong-Ho Kim
The Defined TLR3 Agonist, Nexavant, Exhibits Anti-Cancer Efficacy and Potentiates Anti-PD-1 Antibody Therapy by Enhancing Immune Cell Infiltration. Cancers 15 (24) (2023)
Mirim Hong, Youngki Yoo, Miyoung Kim, Ju Yeon Kim, Jeong Seok Cha, Myung Kyung Choi, Uijin Kim, Kyungyong Kim, Youngsoo Sohn, Donggoo Bae, Hyun-Soo Cho, Seung-Beom Hong
A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization. Molecular cancer therapeutics 20 (6) (2021)